Clopidogrel is a prodrug. It inhibits platelet activation and aggregation by irreversibly binding its active metabolites to P2Y12 ADP receptors on platelets. Dose-dependent inhibition of platelet aggregation can be observed 2 hours after a single oral administration. A repeated daily dose of 75 mg inhibited ADP-induced platelet aggregation on the first day, and the inhibition reached a steady-state between days 3 and 7.
Acute Coronary Syndrome: Start Clopidol with a single 300 mg (4 tablets) oral loading dose and then continue at 75 mg once daily in individuals who need an antiplatelet effect within hours. It will take several days to establish an antiplatelet effect if you start it without a loading dosage.
75 mg once a day orally without a loading dose for recent MI, recent stroke, or established peripheral arterial disease.
It is given orally with or without food.
Clopidol is contraindicated in the following situations: Allergic to any component of the drug or product. Active pathological bleeding, such as a peptic ulcer or intracranial hemorrhage.
Clopidol is a generally well-tolerated medication.
Common side effects: bleeding,
diarrhea, gastrointestinal discomfort, hemorrhage, skin reactions.
Rare side effects: acquired hemophilia, anemia, angioedema, arthralgia, arthritis, bone marrow disorders.
There is no adequate and well-controlled study of pregnant women. It should be used during pregnancy only when clearly necessary. It is not known whether clopidogrel is excreted in human milk. The importance of the drug to the mother should be considered and a decision should be made to stop breastfeeding or discontinue the drug.
Keep below 30°C temperature in a dry place. Protected from light. Do not freeze. Keep out of the reach of children.